Aerpio Pharmaceuticals, Inc.
ARPO · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.00 | -0.01 | 0.08 |
| FCF Yield | -34.84% | -20.88% | -27.15% | -34.43% |
| EV / EBITDA | -0.13 | 11.05 | -0.86 | -2.23 |
| Quality | ||||
| ROIC | -31.82% | -6.86% | -67.55% | -19.10% |
| Gross Margin | 0.00% | 0.00% | 99.38% | 0.00% |
| Cash Conversion Ratio | 0.87 | 1.01 | -0.16 | 1.40 |
| Growth | ||||
| Revenue 3-Year CAGR | 81.15% | 89.26% | 99.92% | 91.44% |
| Free Cash Flow Growth | -326.56% | 23.09% | 21.19% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 2.65 | 14.95 | 0.76 | 2.21 |
| Interest Coverage | 0.00 | 0.00 | 234.72 | 352.97 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.03 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 2,020.86 | 81.61 |